Intellia Therapeutics and CRISPR Therapeutics Announce U.S. Patent Covering CRISPR/Cas9 Ribonucleoprotein … – GlobeNewswire (press release)
|
Intellia Therapeutics and CRISPR Therapeutics Announce U.S. Patent Covering CRISPR/Cas9 Ribonucleoprotein …
GlobeNewswire (press release) CAMBRIDGE, Mass. and BASEL, Switzerland, April 26, 2017 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA) and CRISPR Therapeutics AG (NASDAQ:CRSP), two leading genome editing companies focused on the development of … Variation on CRISPR technology advances potential cures Analysts Set $25.83 Target Price for Crispr Therapeutics AG (CRSP) Crispr Therapeutics AG (CRSP) Coverage Initiated by Analysts at Chardan Capital |
